< Back to previous page
Researcher
Ingrid Arijs
- Disciplines:Urology and nephrology
Affiliations
- Nephrology and Renal Transplantation Research Group (Division)
Member
From18 Feb 2019 → 17 May 2019 - Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Jan 2006 → 17 Feb 2019
Projects
1 - 4 of 4
- Molecular characterization of pathophysiologic pathways in IBD and its therapeutic potentialFrom1 Oct 2013 → 16 Nov 2017Funding: Own budget, for example: patrimony, inscription fees, gifts
- Identification of the role of matrix metalloproteinases (MMP's) in the development and persistence of chronic bowel inflammation.From1 Jan 2013 → 31 Dec 2016Funding: FWO research project
- The role of matrix metalloproteinases in chronic inflammatory bowel diseases: new insights and applications.From3 Nov 2011 → 31 Dec 2016Funding: IWT personal funding - strategic basic research grants
- Study of the earliest lesions in Crohn's disease in the post-operative recurrence model.From1 Oct 2010 → 31 Oct 2015Funding: FWO fellowships
Publications
1 - 10 of 103
- Integrated analysis of transcriptomic and proteomic alterations in mouse models of ALS/FTD identify early metabolic adaptions with similarities to mitochondrial dysfunction disorders(2024)
Authors: Ingrid Arijs, Diether Lambrechts
Pages: 135 - 149 - PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma(2023)
Authors: Sarah Cappuyns, Bram Boeckx, Ingrid Arijs, Aurelie Mechels, Baki Topal, Chris Verslype, Diether Lambrechts, Jeroen Dekervel
- ESTABLISHING A CLINICALLY RELEVANT MOUSE MODEL OF MESENCHYMAL GLIOBLASTOMA FOR STUDYING TME TARGETING TREATMENTS.(2023)
Authors: Ingrid Arijs, Diether Lambrechts, Frederik De Smet
- Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells(2023)
Authors: Diether Lambrechts, Ingrid Arijs
- Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers(2023)
Authors: Diether Lambrechts, Ingrid Arijs
Pages: 1327 - 1338 - Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers(2023)
Authors: Diether Lambrechts, Ingrid Arijs
Pages: 1327 - 1338 - Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors(2023)
Authors: Ingrid Arijs, Diether Lambrechts
Pages: 327 - 338 - Analysis of cell free DNA to predict outcome to Bevacizumab combination therapy in metastatic colorectal cancer patients(2023)
Authors: Tom Venken, Ingrid Arijs, Diether Lambrechts
- Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy(2023)
Authors: Jenny Weng, Gabriele Bergers, Diether Lambrechts, Ingrid Arijs
Pages: 300 - 314 - PRECLINICAL INTERROGATION OF IMMUNOTHERAPY TREATMENT STRATEGIES IN GLIOBLASTOMA (GBM) USING A CLINICALLY RELEVANT DISEASE MODEL(2022)
Authors: Ingrid Arijs, Diether Lambrechts
Pages: 296 - 297